張素琴,湯曉嶼,李玉琴,劉玉峰,劉嬋娟
(1.鄭州大學(xué)第一附屬醫(yī)院小兒內(nèi)科,河南 鄭州 450052;2.鄭州外國(guó)語(yǔ)學(xué)校,河南 鄭州 450001)
1,年齡1~9歲,中位年齡4.2歲;IM組中,男53例,女40例,男女比例為1,年齡1~12歲,中位年齡 5.8歲。2組病例均以男性多見(jiàn),前者好發(fā)年齡為幼兒期及學(xué)齡前期,后者好發(fā)年齡為學(xué)齡前期及學(xué)齡期。對(duì)2組臨床表現(xiàn)、實(shí)驗(yàn)室檢查及預(yù)后進(jìn)行比較。結(jié)果 EB-HPS組在高熱持續(xù)時(shí)間,肝脾腫大程度均明顯高于IM組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);實(shí)驗(yàn)室檢查示血細(xì)胞減少及血清鐵蛋白升高,差異有統(tǒng)計(jì)學(xué)意義(P<0.05);肝功能損傷:EBV-DNA載量,纖維蛋白原減低,甘油三酯升高均明顯高于IM組,差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。EB-HPS組56.0%的患者可在骨髓檢查中見(jiàn)噬血細(xì)胞現(xiàn)象,IM組中僅有9.0%的患者可在骨髓檢查中見(jiàn)噬血細(xì)胞現(xiàn)象。EBV-HPS組死亡率為23.2%,而IM組為0.0%。結(jié)論 兒童EBV-HPS好發(fā)年齡為幼兒期及學(xué)齡前期,IM好發(fā)于學(xué)齡前期及學(xué)齡期,對(duì)EBV感染后存在持續(xù)發(fā)熱,肝脾淋巴結(jié)腫大患兒早期進(jìn)行血常規(guī)、血清鐵蛋白、肝功能、EBV-DNA載量、纖維蛋白原、甘油三酯及骨髓細(xì)胞檢查能夠及時(shí)對(duì)HPS進(jìn)行診斷,減少誤診率及死亡率。
兒童EB病毒相關(guān)性噬血細(xì)胞綜合征與傳單臨床特點(diǎn)比較
張素琴1,湯曉嶼2,李玉琴1,劉玉峰1,劉嬋娟1
(1.鄭州大學(xué)第一附屬醫(yī)院小兒內(nèi)科,河南 鄭州 450052;2.鄭州外國(guó)語(yǔ)學(xué)校,河南 鄭州 450001)
[摘要]目的通過(guò)分析比較兒童EB病毒相關(guān)性噬血細(xì)胞綜合征(EBV-HPS)與傳染性單核細(xì)胞增多癥(IM)患者的臨床表現(xiàn)及實(shí)驗(yàn)室特點(diǎn),提高對(duì)EBV-HPS的認(rèn)識(shí),減少誤診,降低死亡率。方法回顧性分析45例EBV-HPS患者及同期收治的93例IM患者。EB-HPS組中,男24例,女21例,男女比例為
[關(guān)鍵詞]EB病毒;噬血細(xì)胞綜合征;傳染性單核細(xì)胞增多癥;預(yù)后
EB病毒(Epstein-Barr virus,EBV)是一種常見(jiàn)人類8種皰疹病毒之一,屬Y皰疹病毒,人群感染率極高,臨床上可以引起許多種疾病。其中兒童約有50%的EBV原發(fā)性感染表現(xiàn)為傳染性單核細(xì)胞增多癥(infectious mononucleosis,IM)[1],部分可進(jìn)展為EBV相關(guān)性噬血細(xì)胞綜合征(EBV-associ-atedhemophagocytic syndrome,EBV-HPS)。HPS是由多種致病因素引起的淋巴細(xì)胞和組織細(xì)胞過(guò)度增殖,大量炎癥因子被分泌,從而引起多器官炎癥反應(yīng)的一組臨床綜合征。起病急、病情進(jìn)展迅速、病死率高。其特征是發(fā)熱、肝脾淋巴結(jié)腫大、不同程度的血細(xì)胞減少,肝功能損害。HPS分為原發(fā)性和繼發(fā)性2大類。原發(fā)性HPS多與常染色體或性染色體遺傳有關(guān)。繼發(fā)性HPS與感染、腫瘤、自身免疫病、器官移植術(shù)后等多種因素有關(guān)。臨床以繼發(fā)性HPS多見(jiàn)。HPS一旦發(fā)生病情兇險(xiǎn),且有時(shí)與基礎(chǔ)疾病病情變化難以區(qū)分,容易延誤診治,因此及時(shí)診療至關(guān)重要[2]。
1資料與方法
1.1一般資料入組鄭州大學(xué)第一附屬醫(yī)院2010年1月至2015年12月收治的EBV-HPS患者45例及同期收治的IM患者93例,HPS診斷標(biāo)準(zhǔn)均符合2004年國(guó)際組織細(xì)胞學(xué)會(huì)修訂的HPS診斷標(biāo)準(zhǔn)[3]。組織病理學(xué)證據(jù):骨髓檢查或脾臟、淋巴結(jié)活檢見(jiàn)組織細(xì)胞增生并伴噬血細(xì)胞現(xiàn)象,EBV-HPS符合HPS診斷標(biāo)準(zhǔn),同時(shí)具備EBV-IgM抗體陽(yáng)性[4]。IM的診斷標(biāo)準(zhǔn)按照《血液病診斷及療效標(biāo)準(zhǔn)》中IM的診斷標(biāo)準(zhǔn)[5]。
2結(jié)果
1.2臨床表現(xiàn)EBV-HPS患者熱程長(zhǎng),多為高熱,肝脾淋巴結(jié)腫大的程度較IM組顯著,但咽峽炎不明顯,一般無(wú)分泌物。2組皮疹發(fā)生率及淋巴結(jié)腫大發(fā)生率比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P均>0.05)。見(jiàn)表1。
表12組患者臨床資料比較
組別n熱程熱峰咽峽炎/%皮疹/%肝臟腫大(肋下cm)脾臟腫大(肋下cm)淋巴結(jié)腫大/%IM組937.339.491.219.13.42.180.3EBV-HPS組4519.640.128.720.45.84.385.9Z5.284.3711.250.024.254.020.07P<0.05<0.05<0.05>0.05<0.05<0.05>0.05
2.3實(shí)驗(yàn)室檢查EBV-HPS患者外周血三系降低、肝功能損害程度均較IM患者顯著,乳酸脫氫酶和天冬氨酸氨基轉(zhuǎn)移酶顯著高于IM患者,但是IM組變異淋巴細(xì)胞中位數(shù)達(dá)17.5%,顯著高于EBV-HPS組,EBV-HPS患者血清鐵蛋白顯著增高,纖維蛋白原明顯下降。2組患者均進(jìn)行骨髓檢查,IM組中有9.0%的患者骨髓中可以見(jiàn)到的組織細(xì)胞吞噬血細(xì)胞現(xiàn)象,EBV-HPS組有56.0%的患者骨髓中可以見(jiàn)到的組織細(xì)胞吞噬血細(xì)胞現(xiàn)象。多數(shù)IM患者經(jīng)抗病毒或丙種球蛋白及對(duì)癥治療后,體溫降至正常,外周血白細(xì)胞逐漸恢復(fù)正常,變異淋巴細(xì)胞迅速減少;肝脾縮小,而EBV-HPS患者經(jīng)抗病毒治療則無(wú)明顯好轉(zhuǎn),多持續(xù)高熱需激素治療,甚至需聯(lián)合應(yīng)用環(huán)孢霉素A、VP-l6以及丙種球蛋白治療。本組EBV-HPS患者除2例放棄治療外,余患者給予積極治療原發(fā)病,死亡率仍高達(dá)23.2%。見(jiàn)表2。
表22組患者實(shí)驗(yàn)室檢查及治療效果比較
組別白細(xì)胞計(jì)數(shù)/(×109·L-1)變異淋巴細(xì)胞/%血紅蛋白/(g·L-1)血小板計(jì)數(shù)/(×109·L-1)丙氨酸氨基轉(zhuǎn)移酶/(u·L-1)天冬氨酸氨基轉(zhuǎn)移酶/(u·L-1)乳酸脫氫酶/(u·L-1)IM組10.217.5114.5179.653.652.8485.6EBV-HPS組3.48.380.335.6110.8140.51563.5Z4.234.085.346.282.582.894.85P<0.05<0.05<0.05<0.05<0.05<0.05<0.05組別血清白蛋白/(g·L-1)血清鐵蛋白/(g·L-1)纖維蛋白原/(g·L-1)EBV-DNA載量/(copies/mL)骨髓可見(jiàn)吞噬細(xì)胞/%死亡率/%IM組40.5756.02.58102~1039.00.0EBV-HPS組28.63456.81.02103~10656.023.2Z2.487.452.243.584.2311.28P<0.05<0.05<0.05<0.05<0.05<0.05
3討論
EBV感染機(jī)體后多數(shù)是無(wú)癥狀性的,急重型EBV感染臨床可以表現(xiàn)為IM,IM多好發(fā)于男性,好發(fā)年齡為學(xué)齡前期及學(xué)齡期。絕大多數(shù)IM呈良性自限性過(guò)程,或經(jīng)抗病毒及對(duì)癥治療后預(yù)后良好,但是,仍有部分人群EBV感染后會(huì)發(fā)生EBV-HPS,HPS是一組以組織細(xì)胞良性增生伴吞噬血細(xì)胞為病理特征的臨床綜合征,繼發(fā)性HPS以感染最為多見(jiàn),其中62.2%為EBV感染所致[6]。其中的機(jī)制目前尚不完全清楚,可能與以下幾個(gè)因素有關(guān)[7]:1)NK細(xì)胞活性異常:研究顯示,NK細(xì)胞可能在機(jī)體對(duì)EBV感染后免疫反應(yīng)中起到重要的作用。EBV-HPS患者的NK細(xì)胞活性較低甚至缺陷,本組中EBV-DNA拷貝數(shù)可達(dá)103~106·mL-1;IM患者具有較高的NK細(xì)胞活性,而EBV-DNA拷貝數(shù)一般為102~103·mL-1。因此,推測(cè)NK細(xì)胞在EBV感染早期可能起到阻止IM進(jìn)展到EBV-HPS的保護(hù)作用,NK細(xì)胞被認(rèn)為在調(diào)節(jié)慢性病毒感染中起重要作用,觀察發(fā)現(xiàn),NK細(xì)胞的數(shù)量與疾病的嚴(yán)重程度呈負(fù)相關(guān),提示了NK細(xì)胞在控制病毒的復(fù)制中起著重要作用;2)EBV感染的細(xì)胞類型:在IM中,EBV主要感染B淋巴細(xì)胞,而在慢性活動(dòng)性EBV感染和EBV-HPS時(shí),EBV可直接感染T/NK淋巴細(xì)胞,引起被感染機(jī)體嚴(yán)重的免疫缺陷,EBV清除障礙,患者體內(nèi)EBV高載量,導(dǎo)致EBV持續(xù)性感染。因此認(rèn)為,EBV感染的細(xì)胞類型和被感染者體內(nèi)EBV高載量是EBV-HPS的主要激發(fā)因素,而被激活的巨噬細(xì)胞則釋放出TNF、IL-6等炎癥性細(xì)胞因子,這些細(xì)胞因子可使多臟器受到損害,遂致發(fā)熱、黃疸、肝脾腫大、肝功能異常、全血細(xì)胞減少、脂代謝異常,并伴有免疫功能紊亂等多種臨床癥狀[8]。EBV可作為隱性感染源在健康人體的B淋巴細(xì)胞內(nèi)終身存在。單純的EBV感染其實(shí)并不可怕,可怕的是其引起的免疫系統(tǒng)功能紊亂而導(dǎo)致的相關(guān)性疾病?;颊唧w內(nèi)免疫功能的改變是引起機(jī)體機(jī)能損害的關(guān)鍵環(huán)節(jié),而且這種改變是復(fù)雜的,目前的相關(guān)研究還不夠全面與系統(tǒng),還需要更進(jìn)一步的研究,以便在EBV感染相關(guān)性疾病的診斷及治療過(guò)程中能有的放矢[9]。
參考文獻(xiàn):
[1]Macsween KF,Crawford DH.Epstein-Barr virus-recent advances[J].Lancet Infect Dis,2003,3(3):131-140.
[2]呂朝治,馬維維,趙苗苗,等.EB病毒感染及其他病因所致的噬血細(xì)胞綜合征患兒臨床特征對(duì)比分析[J].中國(guó)醫(yī)師進(jìn)修雜志,2014,37(9):63-65.
[3]Henter JI,Horne A,Aricó M,et al.HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J].Pediatr Blood Cancer,2007,48(2):124-131.
[4]Imashuku S.Clinical features and treatment strategies of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis[J].Crit Rev Oncol Hematol,2002,44(3):259-272.
[5]張之南.血液病診斷及療效標(biāo)準(zhǔn)[M].北京:科學(xué)出版社,2007.
[6]Quan TE,Roman RM,Rudenga BJ,et al.Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells[J].Arthritis Rheum,2010,62(6):1693-1701.
[7]常穎,陳佳美,曹慧,等.EB病毒感染相關(guān)性噬血細(xì)胞綜合征患者的臨床診斷與骨髓細(xì)胞學(xué)特點(diǎn)分析[J].中華醫(yī)院感染學(xué)雜志,2016,26(4):736-738.
[8]Filipovich AH.Hemophagocytic lymphohistiocytosis (HLH) and related disorders[J].Hematology Am Soc Hematol Educ Program,2009:127-131.
[9]魏小平,莊云菁,陳濤.感染及淋巴瘤所致噬血細(xì)胞現(xiàn)象與免疫功能的相關(guān)性及意義[J].廣東醫(yī)學(xué),2014(10):1521-1524.
Clinical Characteristics Comparison of Children EB Virus Correlation Hemophagocytic Syndrome and Infectious Mononucleosis
Zhang Suqin1,Tang Xiaoyu2,Li Yuqin1,Liu Yufeng1,Liu Chanjuan1
(1.DepartmentofPediatrics,theFirstAffiliatedHospitalofZhengzhouUniversity,Zhengzhou450052,China;2.ZhengzhouForeignLanguageSchool,Zhengzhou450001,China)
[Abstract]ObjectiveTo compare the clinical manifestations and laboratory tests of EB virus hemophagocytic syndrome (EBV-HPS) and infectious mononucleosis (IM),to enhance the understanding of the EBV-HPS,reduce misdiagnosis and mortality.MethodsForty-five patients EBV-HPS and 93 patients with IM were analyzed retrospectively.In the EBV-HPS group,there were male 24 patients,female 21 patients,gender distribution 1,age range of one to nine,mean age 4.2.In the IM group,there were male 53 patients,female 40 patients,gender distribution 1,age range of one to twelve,average age 5.8.For both groups note a male dominance,the former high paroxysmal ages were infancy and pre-school age,and the latter high paroxysmal ages were pre-school age and school age.ResultsAll the clinical manifestation,laboratory examination and prognosis were reviewed and analyzed in this study.The results showed that during the hyperpyrexia period,hepatosplenomegaly in the EBV-HPS group was apparently higher than that in the IM group,the results were statistically significant (P<0.05).Laboratory examination showed that hemocytopenia,serum ferritin rised,hepatic injury,EBV-DNA dose decrease,fibrinogen decrease,and triglyceride increase were apparently higher than those in the IM group.Almost 56.0% of patients in the EBV-HPS group experienced the hemophagocytosis in bone marrow which were only developed 9.0% of patients in the IM group.The regular antiviral treatment and symptomatic treatment of EBV-HPS were invalid with high fatality.The clinical course was especially dangerous.According to the HLH-2004 after solution treatment,the mortality of EBV-HPS patients was 23.2%,while no death patients in the IM group.ConclusionEBV-HPS often presented in patients from infancy to pre-school age,and IM often present in patients from pre-school age to school age.The child who suffered from persistent fever and hepatosplenomegaly after EBV infection,should do the routine blood tests,serum ferrium,hepatic function test,EBV-DNA dose,fibrinogen,triglyceride,bone marrow cells to clarify HPS diagnosis.Only in this way can reduce the misdiagnosis rate and mortality.
[Key words]Epstein-Barr virus; hemophagocytic syndrome; infectious mononucleosis; prognosis
作者簡(jiǎn)介:張素琴(1983-),女,主治醫(yī)師,主要從事小兒內(nèi)科疾病的臨床診治工作。
DOI:10.3969/j.issn.1673-5412.2016.03.019
[中圖分類號(hào)]R725.5
[文獻(xiàn)標(biāo)識(shí)碼]A
[文章編號(hào)]1673-5412(2016)03-0249-04
(收稿日期:2016-02-13)